Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:36:48 16/07/2024 pm IST			5-day change	1st Jan Change
40.86 ^USD	+1.78%		+0.02%	-20.35%

02:42pm	Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	MT
15/07	Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM

Bristol-Myers Squibb Company Reaffirms Earnings Guidance for the 2013

January 26, 2012 at 09:00 pm IST

Bristol-Myers Squibb Company reaffirmed earnings guidance for the 2013. The company last confirmed 2013 floor guidance of $1.95 to non-GAAP EPS in July.

Latest news about Bristol-Myers Squibb Company

Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	06:12pm	MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM	15/07
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	12/07	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	11/07	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43	10/07	MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	02/07	CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	01/07	MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin	01/07	CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	27/06	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	27/06	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	26/06	MT
Bristol Myers: accelerated approval in colorectal cancer	24/06	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	22/06	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	22/06	MT
US FDA approves Bristol Myers' colorectal cancer therapy	21/06	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	21/06	MT
Bristol Myers: application validated for subcutaneous Opdivo	21/06	CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	21/06	CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	20/06	CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors	19/06	CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	19/06	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	18/06	MT

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 11:36 pm IST

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.15 USD

Average target price

52.74 USD

Spread / Average Target

+31.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-20.35%	81.39B
ELI LILLY AND COMPANY	+62.89%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.03%	359B
MERCK & CO., INC.	+16.02%	325B
ABBVIE INC.	+8.89%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.44%	177B
PFIZER, INC.	+1.84%	165B

Other Pharmaceuticals